<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUORESCEIN SODIUM</span><br/>(flure'e-seen)<br/><span class="topboxtradename">Fluorescite, </span><span class="topboxtradename">Fluor-I-Strip, </span><span class="topboxtradename">Fluor-I-Ful-Glo, </span><span class="topboxtradename">Funduscein<br/></span><b>Classifications:</b> <span class="classification">ophthalmic diagnostic agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10%, 25% injection; 2% ocular solution; 0.6 mg, 1 mg, 9 mg strips</p>
<h1><a name="action">Actions</a></h1>
<p>Mildly antiseptic fluorescent dye related chemically to phenolphthalein that demonstrates defects of the corneal epithelium.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Any break in the epithelial tissue allows the dye to enter the tissue. Epithelial damage will appear as a bright green area.</p>
<h1><a name="uses">Uses</a></h1>
<p>An aid in fitting hard contact lenses, applanation tonometry, detecting corneal epithelial defects, and testing potency of
         lacrimal system. Used IV as a diagnostic aid in retinal angiography. Also used as an antidote for aniline dye.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Topical use with soft contact lenses not recommended.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of hypersensitivity, allergies, bronchial asthma; pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diagnostic Aid</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Instillation</span> Instill 12 drops then have patient keep eyelid closed for 60 sec or moisten strip with sterile water, touch conjunctiva
               or fornix with moistened tip, and have patient blink to distribute<br/><br/><span class="indicationtitle">Retinal Angiography</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5 mL of 10% solution or 3 mL of 25% solution injected rapidly in antecubital vein.<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 7.5 mg/kg injected rapidly in antecubital vein<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Avoid touching eyelids or surrounding area with eyedropper when instilling medication.</li>
<li>Fit hard contact lenses: Instill drug with contact lenses in place. Have patient blink several times to distribute dye. Under
            blue light, areas that lack fluorescein will appear black, indicating that contact lens is touching cornea at these points.
         </li>
<li>Test for potency of lacrimal system: One drop of 2% solution is instilled into conjunctival sac. Have patient blink at
            least 4 times. After 6 min, nasal secretions are examined under blue light. Traces of dye in secretions indicate that nasolacrimal
            drainage system is open.
         </li>
<li>Store below 27° C (80° F); keep tightly closed when not in use, and protect from light and freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Special Senses:</span>
<span class="speceff-common">Temporary stinging, burning sensation,</span> conjunctival redness. <span class="typehead">CNS:</span> (IV administration) Headache, paresthesias, pyrexia, convulsions. <span class="typehead">CV:</span> (IV administration) Hypotension, transient dyspnea, acute pulmonary edema, basilar artery ischemia, syncope, <span class="speceff-life">severe shock, cardiac arrest</span>. <span class="typehead">GI:</span> (IV administration) Nausea, vomiting, strong metallic taste following high dosage. <span class="typehead">Body as a Whole:</span> (IV administration) Hypersensitivity (urticaria, pruritus, angioneurotic edema, <span class="speceff-life">anaphylactic reaction</span>). <span class="typehead">Skin:</span> (IV administration) Thrombophlebitis at injection site, temporary discoloration of skin and urine. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Have facilities for treatment of anaphylactic reaction immediately available (e.g., epinephrine 1:1000 for IV or IM use, an
            antihistamine, and oxygen).
         </li>
<li>Discontinue fluorescein immediately if S&amp;S of sensitivity develop.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: IV administration may impart a yellowish orange discoloration to skin and to urine. Skin discoloration usually fades in 612
            h; urine clears in 2436 h.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>